The Department CIBIO is partner of the European Training Network INTEGRATA (Integrating chemical and biological approaches to target NAD production and signaling in cancer) in the framework of the Horizon 2020 Marie Skłodowska-Curie Action for Innovative Training Network (ITN).
INTEGRATA will offer the opportunity to motivated international Early Stage Researchers (ESRs) to experience a highly interdisciplinary and intersectoral training in cancer metabolism and drug discovery, focusing specifically on NAD production and on NAD/nucleotide signaling as targets for the development of new cancer therapeutics.
The project started is coordinated by Prof. Alessio Nencioni, University of Genoa (Italy) and involves in Trento prof. Alessandro Provenzani, Principal Investigator of the Genomic Screening Laboratory at CIBIO.
Other laboratories involved in the project are based at University of Genoa (IT), the University Hospital Bonn (UKB) (DE), Karolinska Institutet (SE), Centre Hospitalier Universitaire Vaudois (CH), University of Leipzig (DE), University of Torino (IT), University of Sevilla (ES), University of Hamburg (DE), and three companies Innovamol (IT), Novimmune (CH), Heidelberg pharma (DE).
ESRs will be recruited to work in laboratories with expertise in cancer biology, drug design, organic chemistry to develop and validate in different model systems new chemical entities, conjugated an unconjugated monoclonal antibodies.
In addition to their individual scientific projects, the successful candidates will benefit from further continuing education, which includes international mobility through internships and secondments at the partner's premises, a variety of training modules as well as transferable skills courses and active participation in workshops and conferences.
The INTEGRATA Consortium is now launching fourteen (14) positions for Early Stage Researchers (ESRs) for doctoral studies at the premises of the thirtheen (13) beneficiaries’ organisations.
In this framework, a position for an ESR working in “Annotating and overcoming resistance to NAMPT inhibitors in cancer cells” is opening at the Provenzani’s Lab. The ESR will investigate the molecular mechanisms of resistance to NAMPT inhibitors of cancer cells and how internal and secreted NAMPT contribute to resistance to anti-cancer agents (for full description of the position and the other open position, please follow the link below).
Interested applicants have to meet the Marie Sklodowska-Curie Actions eligibility requirements as follows:
- Researcher status: Early-Stage Researchers (ESRs) are young researchers who, at the date of recruitment, are in the first four years (full-time equivalent research experience) of their research careers and have not been awarded a doctoral degree;
- Nationality: Applicant ESRs can be of any nationality
- Mobility requirements: Applicant ESRs must not have resided or carried out their main activity (work, studies, etc.) in the country of the recruiting organisation for more than 12 months in the 3 years immediately before the recruitment date.
To get the complete description of the open positions, please look at the file in the downlod box
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 813284.